While a number of anti-glycating agents are in the development stage, Aminoguanidine has been available in Europe for many years.
As more European suppliers have begun offering aminoguanidine, the cost has declined sharply, making this an inexpensive addition to one's life extension regimen.
Glycosylation is the pathological binding of glucose to an amino acid that results in the formation of a non-functioning structure in the body. Diabetics suffer from an accelerated rate of glycosylation, and many of the premature degenerative diseases common in Type I and Type II diabetes is attributed to the glycosylation process.
As organisms age, glycosylation becomes a major factor in the development of aging-relating disease. Some gerontologists believe that glycosylation is the most significant biologic event responsible for the degenerative diseases of arterial system, the eye and the brain. Those seeking to add healthy years to their lives have a significant interest in interfering with the glycosylation process.
Oxidative damage plays a role in the glycosylation process, which helps to explain why antioxidant supplements have shown benefit in preventing diseases associated with diabetes. It requires a lot more than antioxidant, however, to adequately block age-related glycosylation.
Healthy adults may consider taking 300mg of aminoguanidine a day (or every other day), while diabetics could consider a maximum dose of 600mg a day. Semi-monthly CBC and chemistry blood tests should be considered in order to protect against any unknown toxicities.